Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. - Test2 - elhamkhani - TriplyDB

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

http://www.wikidata.org/entity/Q34122822

about

Patient-derived tumour xenografts as models for oncology drug development Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies One mouse, one patient paradigm: New avatars of personalized cancer therapy Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Proton-shuttling lichen compound usnic acid affects mitochondrial and lysosomal function in cancer cells Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma The future of patient-derived tumor xenografts in cancer treatment.Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial Therapeutic options for the management of pancreatic cancer.Patient-derived xenograft models: an emerging platform for translational cancer research Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.Molecular targeted approaches for treatment of pancreatic cancer.Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells.Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology.Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?Patient-derived xenografts as tools in pharmaceutical development.The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.Patient-derived tumor xenograft models for melanoma drug discovery.A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy.Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.The Generation and Application of Patient-Derived Xenograft Model for Cancer Research.Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo.Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.MTOR inhibitor-based combination therapies for pancreatic cancer.

P2860

Q24604068-47856F7E-F82E-4143-9BC7-20F490C37EC7 Q24630174-4E9844E6-08AA-4B37-A98B-C97FED6C48CF Q26799714-B1EE7125-FD9C-4D43-BB8C-BB903A43B493 Q27023342-0F11FAC9-3CF0-444F-A69E-72740888D5D5 Q28066268-BAECB018-B1DB-44D0-A161-C06E749FEEC9 Q28485469-E5463338-EEDC-4C09-AE50-26DBDC86D07E Q28534618-ACA1B1B9-3A7B-4E4A-A681-59026BC5B438 Q33361578-847CC908-67E9-4099-94DC-1AB9FA9BC854 Q33410691-8C6FB7E9-CC7C-4E10-8CF6-BC6FD99F7BC7 Q34093776-986AE5EC-047B-4073-AB6B-9B208191405E Q34205518-95E57E1F-A8D6-44C0-86BE-F1A84970C27D Q35034700-D9520777-F37D-4649-8180-77171B5B2AA4 Q35179190-CACB70CA-EFBD-46A9-8775-F715CD10EB76 Q36123027-AC582909-5F41-4AFD-BBAE-675A62916A03 Q36174910-B595D141-009C-4381-A4AA-EF4FBF609E4C Q36204291-285E3AC3-C6CD-4111-A15E-CD6F2B7132E5 Q36723405-811DCE80-C7A9-4C2B-96B5-4A9C6E4BF4A1 Q37030911-FDAA8DC5-C437-4FB8-820E-3A53E7153A5B Q37096469-211268D9-6526-4D59-BF54-0F26C12FBA4D Q37342746-D2C9FEE2-E9F2-4CD7-8CD0-918A6CC3B243 Q37617955-A17A23D3-D534-4348-9861-414F72DBD29C Q38732336-85073024-8D51-4B82-B6BA-9F13459CC23B Q38842150-9405C3D6-C5C0-46BD-9C8F-CF8AB4325F54 Q38907413-138EB85C-A2C4-4096-8F74-ADEFD72994D3 Q39015140-D8507DDB-8620-468B-8860-597F85AB9295 Q39024706-83AB84E5-289B-4B1F-8480-8580C85AF347 Q39205923-DAD7087B-6C5B-4426-A5C4-DB4C0D096211 Q43117536-2A580041-DBCA-48EB-8B33-D36821A8B05F Q45068320-C15337C6-BD51-4488-9D94-09F37A9799E6 Q49284173-5A53CE77-7AA8-4A91-BFF9-D45DE04697FF Q49450339-866765D3-D129-428F-81A4-3A0AA499B177 Q49497626-BF1168D3-DF0F-429A-9322-91EDABC483B6 Q49560871-CCA8508B-E82C-49B7-9705-B88E7FEB37E3

P2860

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

http://www.wikidata.org/entity/Q34122822

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@ast

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@en

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@nl

type

label

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@ast

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@en

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@nl

prefLabel

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@ast

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@en

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

@nl

P1433

Q34122822-60C39EB6-8AEB-4FDF-A1CF-21220D920AF0

P1476

Q34122822-8DDD2DDA-0CB9-4E12-8646-90DB05C7C103

P2093

Q34122822-1699723D-352A-49D1-813D-FC69371A3C1A

Q34122822-262D4DDF-098D-4EC2-B89A-4DF870F88A5E

Q34122822-40E976B8-0F8F-420C-A5FB-EAB029C3C437

Q34122822-507E3D90-87F7-4BE3-9163-E72E6CC1D71A

Q34122822-51601372-6D0D-4632-8B8C-79592B525076

Q34122822-5DD82FA6-0958-468C-92B1-5D9E4645850E

Q34122822-808B6092-170F-4DC7-9892-4221E8F3E745

Q34122822-97AA0C3F-272B-4598-BE0F-4570163FE173

Q34122822-9BDD2CC5-4C76-41B6-9001-F051138289A0

Q34122822-9CE27F1F-C86F-4825-B703-ADD294071164

P2860

Q34122822-006EB149-E2CE-43EE-A07F-735A58E3967B

Q34122822-1106F896-F4EA-41CE-A4BE-347EB15AA0BD

Q34122822-16866B71-22BA-434A-8E0F-345F87190A00

Q34122822-180DD96C-514D-4260-A4BC-400C5608852D

Q34122822-1E4A6ACE-042F-4921-A20F-DD14C2711FBA

Q34122822-254AB43B-5C30-4A73-8A78-C392402E1C6A

Q34122822-282CF4F1-F5EF-482E-9C93-F4FB1CA06FB2

Q34122822-2D73A6EC-C993-4DC8-A311-C3C50A2AE994

Q34122822-327CA6CE-8052-43CB-920D-59A10C54427C

Q34122822-349B4A84-4ABB-41A6-B3AD-BC4D947841D0

P2888

Q34122822-341B73D1-B547-48C9-9078-B8EAA3D3F55B

P304

Q34122822-96616EF4-0AAF-4CAA-82F3-7DB264535F4D

P31

Q34122822-E3CCAC81-2ECB-4B9F-BFA8-00DC535E7933

P356

Q34122822-AA4094E6-2FB2-4BEC-8E2E-3CB4C234CFCA

P407

Q34122822-9B90E31E-9C13-4373-BEC3-26D684BA8812

P433

Q34122822-DEEF8D59-0755-4F44-819E-881C8C70247D

P478

Q34122822-31F919C7-0D93-410A-8269-6B3141343AA0

P50

Q34122822-73AFF7E3-FD4C-4627-8646-2C4D2AAA37F3

Q34122822-9E376121-D290-4FB0-ACC4-3876C194DC84

P577

Q34122822-83817118-0B23-4DBD-8B7E-BF77B7002016

P5875

Q34122822-9E97C08A-5B71-4935-8EC0-DC0A3C28F7D8

P6179

Q34122822-5CB1A02A-D249-47B4-BE85-D9163A02C21A

P698

Q34122822-AAA7E2D5-514F-4577-884C-4853B535811E

P932

Q34122822-A1FE44C0-0E6A-4669-B0C7-499761D25FB1

P356

P1433

British Journal of Cancer

P1476

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

@en

P2093

A Jimeno

http://www.w3.org/2001/XMLSchema#string

B Rubio-Viqueira

http://www.w3.org/2001/XMLSchema#string

C Iacobuzio-Donahue

http://www.w3.org/2001/XMLSchema#string

D Laheru

http://www.w3.org/2001/XMLSchema#string

I Garrido-Laguna

http://www.w3.org/2001/XMLSchema#string

M A Rudek

http://www.w3.org/2001/XMLSchema#string

M Angenendt

http://www.w3.org/2001/XMLSchema#string

M Barrett

http://www.w3.org/2001/XMLSchema#string

M C Villaroel

http://www.w3.org/2001/XMLSchema#string

M Uson

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Targeting the mTOR signaling network for cancer therapy

Somatic mutation and gain of copy number of PIK3CA in human breast cancer.

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Cancer statistics, 2009

Exploiting the PI3K/AKT pathway for cancer drug discovery

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

P2888

P304

649-655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605819

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45389529

http://www.w3.org/2001/XMLSchema#string

P6179

1052396491

http://www.w3.org/2001/XMLSchema#string

P698

20664591

http://www.w3.org/2001/XMLSchema#string

P932

2938261

http://www.w3.org/2001/XMLSchema#string